We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Environmental Protection Agency said Friday it cited Dow Chemical Co. for violating the Clean Air Act at the company's Midland, Mich., facility.
Shares in ConjuChem Biotechnologies Inc. fell sharply Friday morning after the company said it had halted a Phase 2 drug trial due to the death of a patient.
Abbott Laboratories' (ABT) membership in the Association of the British Pharmaceutical Industry was reinstated effective July 1, following its suspension in February.
Merck & Co.'s president of its U.S. human health division, Brad Sheares, is leaving the company after nearly 20 years, the drug maker confirmed Thursday, in what could be a sign of a management shake up.
Forest Laboratories, Inc. said that the U.S. District Court for the District of Delaware has determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro, is both valid, enforceable and infringed by Ivax/Teva's proposed generic product,
thereby confirming Forest's and Lundbeck's patent rights for Lexapro, which expire in March 2012.
Abbott Laboratories and AstraZeneca will collaborate on the development and marketing of a combination treatment targeting three blood lipids -- LDL "bad" cholesterol, HDL "good" cholesterol, and triglycerides -- in a single pill.
The FDA recently approved MedImmune's supplemental biologics license application to use a new technology to develop two influenza vaccines, according to the company.
The FDA canceled a closed meeting of its Blood Products Advisory Committee one day after a government watchdog group filed a lawsuit to force the agency to hold the hearing in the open.
A U.S. district judge declined on to issue a preliminary injunction blocking two companies from exclusively selling their generic versions of Merck & Co. Inc.'s Zocor cholesterol drug.